Table 1.
Age | Sex | Disease | Valve | Time 1 | Mechanical support | Time 2 | LVAD | Treatment | |
---|---|---|---|---|---|---|---|---|---|
Case 1 | 28 | Male | D‐HCM | None | 8 d | IABP | 10 d | Jarvik 2000 | Electrical defibrillation, Landiolol |
Case 2 | 21 | Male | DCM | Severe MR | 9 d | IABP | 13 d | Heart MateI II | Electrical defibrillation, Amiodarone, Landiolol, Digitalis |
Case 3 | 46 | Male | DCM | Moderate MR | 6 d | PCPS | 7 d | NIPRO VAD | Electrical defibrillation, Amiodarone |
Case 4 | 53 | Male | DCM | Severe MR | 1 m | IABP | 2 m | Jarvik 2000 | Amiodarone, Digitalis |
Case 5 | 42 | Male | DCM | Severe MR | 9 d | IABP | 16 d | Heart Mate II | Amiodarone, Landiolol |
Present case | 38 | Male | DCM | Severe MR | 1 d | IABP, PCPS | 9 d | NIPRO VAD | Amiodarone, Landiolol, Electrical difibrillation |
All cases recovered to sinus rhythm or pacemaker rhythm after LVAD implantation. (i) Time 1 is the interval from occurrence of AF to mechanical support (e.g., IABP, PCPS). (ii) Time 2 is the interval from occurrence of AF to LVAD implantation.
D‐HCM, dilated phase of hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; MR, mitral regurgitation; d, days; m, months; IABP, intra‐aortic balloon pumping; PCPS, percutaneous cardiopulmonary support; LVAD, left ventricular assist device.